Clinical trials: ESCC
Locally Advanced Esophageal Squamous Cell Carcinoma, II-IIIB Stages
Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma
This study is a single center, prospective, single arm exploratory clinical trial aimed at evaluating the efficacy and safety of sequential chemoradiotherapy combined with cetuximab in unresectable locally advanced esophageal…
- Trial name
- NCT06715501
- Testing
- Cadonilimab, radiotherapy, carboplatin, paclitaxel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- First Affiliated Hospital of Ningbo University
Esophageal Squamous Cell Carcinoma
Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification
This is a phase 2 trial investigating the effect and safety of afatinib plus toripalimab in previously treated recurrent or metastasic esophageal squamous cell carcinoma with EGFR overexpression or EGFR amplification.
- Trial name
- NCT04880811
- Testing
- Afatinib, Toripalimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Peking University
Esophageal Squamous Cell Carcinoma
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
This study will explore the efficacy and safety of benmelstobart combined with radiochemotherapy compared to radiochemotherapy alone as neoadjuvant treatment for esophageal squamous cell carcinoma.
- Trial name
- NCT06637163
- Testing
- Benmelstobart+ Paclitaxel + Carboplatin+ Radiotherapy, Paclitaxel + Carboplatin + Radiotherapy
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
ESCC
Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Major objectives to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1/CTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced…
- Trial name
- NCT07493993
- Testing
- lparomlimab and Tuvonralimab Injection in Combination with Nab-Paclitaxel
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma
Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade
The purpose of this study is to observe and evaluate the efficacy and safety of Decitabine plus Penpulimab as second-line therapy for advanced esophageal squamous cell carcinoma treated with PD-1 blockade
- Trial name
- NCT05265962
- Testing
- Decitabine plus Penpulimab
- Volunteers
- 85 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)
This is a prospective, single-arm, phase II clinical study designed to evaluate the efficacy and safety of sintilimab combined with chemotherapy, followed by sequential concurrent chemoradiotherapy as conversion therapy, in…
- Trial name
- NCT06709417
- Testing
- Sintilimab, Chemotherapy, radiotherapy
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
The Neoadjuvant Treatment for Resectable Esophageal Squamous Cell Carcinoma
a Neo-adjuvant Chemotherapy Immunotherapy in Resectable ESCC Study
Research Purpose 1: To evaluate the therapeutic efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in the treatment of resectable locally advanced esophageal squamous cell carcinoma (ESCC) in the…
- Trial name
- ANACIIRE-1 (NCT06472635)
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Zhejiang University
Esophageal Squamous Cell Carcinoma (ESCC)
Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial, designed to evaluate the efficacy and safety of neoadjuvant toripalimab in combination with nab-paclitaxel and platinum versus neoadjuvant…
- Trial name
- TD-NEOE3V3 (NCT06952621)
- Testing
- 3 cycles (Toripalimab + chemotherapy), 3 cycles（DCF）
- Where
- China
- Volunteers
- 390 people
- Sponsor
- Tang-Du Hospital
Esophagus Cancer, Chemotherapy Effects
Docetaxol Plus Cisplatin Versus 5-Fu Plus Cisplatin as 1st-line Chemotherapy in Advanced ESCC Patients
This is a phase III clinical trial to compare the efficacy of docetaxel plus cisplatin versus 5-Fu plus cisplatin in the first line chemotherapy for advanced or metastatic esophageal squamous carcinoma patients.
- Trial name
- NCT03002064
- Testing
- Docetaxel, Fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 358 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma (ESCC)
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
Esophageal cancer is a malignant tumor with high incidence rate and mortality in China. According to the data of the World Health Organization, 324000 new cases and 301000 deaths of esophageal cancer will occur in China in 2020…
- Trial name
- NCT06861777
- Testing
- Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy, chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin, TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)]
- Where
- China
- Volunteers
- 474 people
- Sponsor
- YIN LI
Prognosis of Patients With ESCC
Correlation of Gene Status and Clinical Outcomes in ESCC
The incidence of esophageal squamous cell carcinoma is highly regional and familial. The current treatment plan is based on the stage and location of the tumor.By studying the relationship between the status of different genes…
- Trial name
- ESCC (NCT03831828)
- Where
- China
- Volunteers
- 46 people
- Sponsor
- LiuJunFeng
Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
This is a Phase 1a/1b, open-label, multicenter dose escalation and dose expansion clinical study to evaluate the safety, PK, immunogenicity and preliminary efficacy of IDE034 in participants with locally advanced/metastatic solid…
- Conditions
- Esophageal Squamous Cell Carcinoma, High Grade Serous Ovarian Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- NCT07503808
- Testing
- IDE034
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- IDEAYA Biosciences
Neoplasm, Esophagus, Neoplasm, Squamous Cell
Primary Tumor Burden Score:A Novel Staging Parameter for ESCC After nCRT
In this case-only study, the investigators try to define a novel staging parameter, the Primary Tumor Burden Score (PTBS).
- Trial name
- NCT05839002
- Testing
- nCRT
- Volunteers
- 187 people
- Sponsor
- Fudan University
Esophageal Malignant Neoplasm Primary
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
A prospective trial design was used to evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors in the treatment of locally advanced resectable esophageal squamous cell carcinoma.
- Trial name
- LA-ESCC (NCT06888531)
- Testing
- Neoadjuvant chemoradiotherapy combined with PD-1/PD-L1 inhibitors for the treatment of locally advanced resectable esophageal squamous cell carcinoma
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Henan Cancer Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma
The goal of this clinical trial is to assess the percentage of patients alive at 6 months in elderly patients, not eligible to an platinum-based chemotherapy, but who can received the Tislelizumab treatment alone as first-line…
- Trial name
- SAFE ESO (NCT07205731)
- Testing
- Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1
- Where
- 30 sites in France
- Volunteers
- 95 people
- Sponsor
- University Hospital, Clermont-Ferrand
Esophageal Squamous Cell Carcinoma (ESCC)
Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
This clinical trial aims to preliminarily evaluate the efficacy and safety of adebrelimab combined with albumin-bound paclitaxel and carboplatin as neoadjuvant therapy for borderline resectable locally advanced esophageal…
- Trial name
- NEOCRTEC2501 (NCT07638436)
- Testing
- Adebrelimab Injection
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma (ESCC)
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
The goal of this clinical trial is to evaluate the efficacy and safety of neoadjuvant toripalimab combined with chemotherapy and low-dose radiotherapy in patients with esophageal squamous cell carcinoma who are insensitive to…
- Trial name
- NCT07272291
- Testing
- Toripalimab
- Volunteers
- 48 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
ESCC, Lymph Node Metastasis
Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma
This study aims to develop a predictive model using deep learning and radiomics to assess the likelihood of lymph node metastasis in patients with early-stage esophageal squamous cell carcinoma (ESCC).
- Conditions
- ESCC, Lymph Node Metastasis, Radiomics
- Trial name
- NCT07050576
- Testing
- The prediction model of lymph node metastasis in early esophageal squamous cell carcinoma
- Where
- China
- Volunteers
- 500 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Esophageal Squamous Cell Carcinoma (ESCC)
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer
The purpose of this study is to evaluate the efficacy and safety of KC1036 in combination with PD-1 antibody and platinum-based chemotherapy as a first-line treatment for patients with unresectable locally advanced, recurrent, or…
- Trial name
- NCT07481058
- Testing
- KC1036, Toripalimab, Paclitaxel
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Esophageal Squamous Cell Carcinoma, Tislelizumab
Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
This is a single institution and single-arm phase I/II study to assess the feasibility and efficacy of tislelizumab plus chemoradiation for conversion therapy of patients with locally nonresectable ESCC.
- Conditions
- Esophageal Squamous Cell Carcinoma, Tislelizumab, Chemoradiation
- Trial name
- LATE (NCT05394415)
- Testing
- Tislelizumab, Paclitaxel, Carboplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu Cancer Institute & Hospital